Recent Updates
Recently added Catalysts
SRPT Negative Sentiment

Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights – SRPT

Key Takeaway: Sarepta Therapeutics, Inc. is facing a securities fraud class action lawsuit filed on behalf of shareholders who purchased shares of the company during the class period from June 22, 2023, to June 24, 2025. The lawsuit alleges that the company issued misleading statements regarding the safety of its gene therapy, ELEVIDYS, which has been implicated in serious adverse events. Shareholders are encouraged to register with the Gross Law Firm, which is managing the class action, before the August 25, 2025 deadline to potentially recover losses associated with these statements.
Price reaction · baseline $19.37 (2025-07-09 close) · hit after-hours · 1 other SRPT headline(s) in the window, move may be shared
day 0 close · peak
-1.6%

Market Sentiment Analysis

CONCERNS & RISKS

  • Sarepta's drug ELEVIDYS allegedly poses significant safety risks to patients.
  • Trials for ELEVIDYS failed to detect severe side effects, leading to potential regulatory scrutiny.
  • The company may face increased risks regarding ELEVIDYS's current and future approvals due to adverse events.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
16.8%
average across 4 past catalysts
Lead asset
Eteplirsen
Phase 3 · Muscular Dystrophy, Duchenne

Full Press Release Details

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).
Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: June 22, 2023 to June 24, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.
DEADLINE: August 25, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=156044&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SRPT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 25, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor

Frequently Asked Questions

What is the class period for Sarepta Therapeutics?

The class period for Sarepta Therapeutics is from June 22, 2023, to June 24, 2025.

What allegations are made against Sarepta Therapeutics?

The allegations include misleading statements about the safety and side effects of ELEVIDYS.

How can shareholders participate in the class action?

Shareholders can register to participate in the class action by visiting the provided link.

Is there a deadline to register for the class action?

Yes, the deadline to register is August 25, 2025.

What services does the Gross Law Firm offer to shareholders?

The Gross Law Firm provides portfolio monitoring and status updates for registered shareholders.

Last updated: Jul 10, 2025